EPO-0627 Clinical relevance of evoked potentials for disease progression in early multiple sclerosis and clinically isolated syndrome in the ProVal-MS study [Abstract] / Marie Braun, J. Havla, M. Kowarik, H. Tumani, Lars Behrens, Markus Naumann, H. Zimmermann, J. Kirschke, M. Senel, M. Kerschensteiner, Lino Braadt, Verena Steuerwald, Korbinian Holzapfel, Anna Muzalyova, H. Spengler, M. Mühlau, E. Oswald, M. Hagedorn, B. Sailer, B. Bender, I. Vardakas, N. Sollmann, O. Kohlbacher, H. Kestler, F. Kohlmayer, U. Ziemann, F. Albashiti, Frank Kramer, M. Boeker, P. Uibel, S. Buchka, Iñaki Soto-Rey, Sven Olaf Rohr, U. Mansmann, B. Hemmer, Antonios Bayas

Related documents

• Follow-up of Persons With Multiple Sclerosis#1074876
• Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment#826450
• Relıabılıty and valıdıty of the Two-minute Test wıth Multiple Sclerosis#913296
• Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial#351090
• A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis#1095701